关注并星标CPHI制药在线12月16日,默沙东在其官网宣布,正式终止其抗TIGIT抗体Vibostolimab和抗LAG-3抗体Favezelimab的开发,这一调整标志着默沙东在免疫检查点抑制剂领域的多年心血付诸东流。两天后,默沙东宣布押注的下一个目标。12月18日,默沙东宣布与国内翰森制药合作,默沙东将获得后者一款在研口服小分子GLP-1受体激动剂(GLP-1RA)HS-10535的全球独家...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.